Axogen proposes $85 million public stock offering

Axogen Inc. (NASDAQ: AXGN) announced plans to conduct an underwritten public offering of $85 million in common stock shares, according to a company statement released January 21, 2026.

The peripheral nerve repair technology company intends to grant underwriters a 30-day option to purchase up to an additional $12.75 million of shares. All shares in the proposed offering will be sold by Axogen directly.

Wells Fargo Securities and Mizuho serve as lead book-running managers for the proposed offering, while Canaccord Genuity and Raymond James act as co-managers.

Axogen plans to use net proceeds from the offering to pay off and terminate its term loan facility with Oberland Capital, fund working capital, capital expenditures and other general corporate purposes.

The company filed an automatic shelf registration statement on Form S-3ASR with the Securities and Exchange Commission on January 21, 2026, which became automatically effective upon filing. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC.

The company noted that completion of the offering remains subject to market and other conditions, with no assurance provided regarding whether or when the offering may be completed or the actual size and terms.

Axogen develops and markets surgical solutions for peripheral nerve function restoration. The company's product portfolio includes Avance nerve allografts, Axoguard nerve connectors and protectors, and Avive+ soft tissue matrix products.

You May Also Be Interested In

• Public Storage prices $900M senior notes offering at 4.855% rate
• Everforth upsizes revolving credit facility to $600 million
• Angi Inc. names new chief accounting officer after resignation